PSA provocation by bipolar androgen therapy may predict duration of response to first-line androgen deprivation: Updated results from the BATMAN study.

ABSTRACT:

Background

Previously, we reported results from the Phase II BATMAN study (Bipolar Androgen Therapy for Men with Androgen-ablation Naïve prostate cancer). This study (NCT01750398) was designed to evaluate the safety and efficacy of a treatment regimen consisting of a 6-month lead in-phase of androgen deprivation therapy (ADT) followed by alternating 3-month intervals of bipolar androgen therapy (BAT) and ADT alone. Here we report > 5-year follow-up related to the duration of subsequent ADT, response to first-line androgen receptor inhibitors, safety, and survival in men with castration-sensitive prostate cancer treated on the BATMAN study.

Methods

Univariate Cox regression was utilized to compare overall survival between Responders who achieved a prostate-specific antigen (P

SUBMITTER: Denmeade S 

PROVIDER: S-EPMC9633380 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature